Patents by Inventor Paul C. McDonald

Paul C. McDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10195174
    Abstract: The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: February 5, 2019
    Assignees: SIGNALCHEM LIFESCIENCES CORPORATION, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Paul C. McDonald, Frances E. Lock, Shoukat Dedhar
  • Patent number: 9962398
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 8, 2018
    Assignee: Welichem Biotech Inc.
    Inventors: Claudiu Supuran, Shoukat Dedhar, Paul C. McDonald, Fabrizio Carta
  • Publication number: 20170007627
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Application
    Filed: September 20, 2016
    Publication date: January 12, 2017
    Inventors: Claudiu SUPURAN, Shoukat DEDHAR, Paul C. MCDONALD, Fabrizio CARTA
  • Patent number: 9463171
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: October 11, 2016
    Assignee: Welichem Biotech Inc.
    Inventors: Claudiu Supuran, Shoukat Dedhar, Paul C. McDonald, Fabrizio Carta
  • Publication number: 20140303103
    Abstract: The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 9, 2014
    Inventors: Paul C. McDonald, Frances E. Lock, Shoukat Dedhar
  • Publication number: 20140148400
    Abstract: Derivatized coumarin-based pharmaceutical compositions and methods to use them are provided. The compositions are characterized in that they inhibit the activity of tumor-related CAIX and CAXII to a greater degree than they inhibit the activity of CAI and CAII. The compositions can be used to suppress tumor growth and/or suppress tumor metastases in a mammal.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 29, 2014
    Applicants: METASIGNAL THERAPEUTICS INC., CNRS-DIRE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventors: Claudiu Supuran, Shoukat Dedhar, Fabrizio Carta, Jean-Yves Winum, Paul C. McDonald
  • Patent number: D746584
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 5, 2016
    Inventor: Paul C. McDonald